125031

Neulasta is a leukocyte growth factor used to decrease the incidence of infection—manifested by febrile neutropenia—in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

It refers to a notable 2015 paper in Physical Review D titled "Self-similar inverse cascade of magnetic helicity driven by the chiral anomaly" (Phys. Rev. D 92, 125031 ). This research explores how magnetic fields behave in chiral plasmas, which is relevant to understanding the early universe. 125031

In the medical field, is the Biologics License Application (BLA) number assigned by the FDA to Neulasta (pegfilgrastim) . Neulasta is a leukocyte growth factor used to